Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?
It is no secret that in the field of biotech, small- to mid-cap companies that develop innovative therapies for difficult-to-treat diseases (such as cancer) and a variety of rare conditions are often acquired by large-cap players for billions of dollars. Last year, the biggest ever biotech deal happened when Bristol Myers Squibb (NYSE: BMY) acquired Celgene for $74 billion.
Today, let's take a look at a company that is at the forefront of battling chronic hepatitis B and has the potential to be acquired by its research and development partner.
Image source: Getty Images.
Source Fool.com
